Merakris Therapeutics — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Merakris Therapeutics, founded in 2015 and based in Durham, NC, is an emerging leader in regenerative medicine with a unique focus on cell-free therapeutics. The company leverages cell-derived proteins and extracellular matrix technology to develop products for advanced wound care and ophthalmology. Its lead investigational drug, MTX-001, is in clinical development following positive FDA interactions, positioning Merakris to address significant unmet needs in chronic wound healing. The company operates as a private, science-led organization advancing both commercial products and a robust clinical pipeline.

Wound HealingOphthalmology

Technology Platform

Proprietary platform for isolating and formulating cell-secreted proteins and nano vesicles (e.g., exosomes) from immunologically privileged human tissues (e.g., amniotic membrane/fluid) to create cell-free regenerative biologics.

Opportunities

The large and growing global advanced wound care market, driven by diabetes and aging demographics, presents a major opportunity.

MTX-001's cell-free, off-the-shelf biologic approach could capture significant market share by offering a standardized and potentially superior alternative to existing cell-based or complex biologic therapies.

Risk Factors

The company faces clinical development risk, as MTX-001 must succeed in later-stage trials.

Financial risk is present as a private company reliant on external funding.

Commercialization risk includes competition and the challenge of securing reimbursement in a crowded wound care market.

Competitive Landscape

Merakris competes in the advanced wound care market against large medtech companies (e.g., Smith & Nephew, 3M, Integra LifeSciences) offering various dressings and devices, and biotech firms developing cell-based therapies (e.g., Organogenesis) or growth factor products. Its cell-free biologic platform aims to differentiate by combining biologic activity with a more scalable and consistent product profile than cell-based competitors.

More companies in Regenerative Medicine →More companies in United States →